Long-acting HIV prevention
Lenacapavir and cabotegravir injections for HIV pre-exposure prophylaxis.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 18, 27, 39, 24, 37.
New guidelines and consensus this year
All papers from the last 12 months
543 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Analytical description of adverse events with long-acting injectable cabotegravir and rilpivirine in people living with HIV: a large multicentre prospective observational cohort study (SCOLTA)HIV Res Clin Pract2026 Dec 31PMID 42765669
- Italy is ready-extended PrEP cascade, and determinants of intention to use long-acting PrEP and unmet PrEP needs among men who have sex with men, trans* individuals, heterosexual women, and menHIV Res Clin Pract2026 Dec 31PMID 42186205
- Successful initiation of fully parenteral antiretroviral therapy in a treatment-naïve person with HIV-1 infection and intestinal failureHIV Res Clin Pract2026 Dec 31PMID 41964115
- Investing in enhanced HIV prevention among young men who have sex with men in Brazil: insights from fiscal health modelingJ Med Econ2026 DecPMID 42543243
- Persistent injection-site nodules visible on cross-sectional imaging: clinical experience with injectable lenacapavir and review of the literatureAIDS2026 Nov 1PMID 42826229
- Tolerability and Virologic Outcomes after Transition from Long-Acting Injectable ART to Oral ARTAIDS Patient Care STDS2026 NovPMID 42728773
- Narrative Review of Two-Drug Regimens in Modern HIV Care: Driving Innovation, Flexibility, and Quality of LifeInfect Dis Ther2026 NovPMID 42728470Review
- Cabotegravir and rilpivirine resistance-associated mutations among people with newly diagnosed HIV-1 in the NetherlandsAIDS2026 Nov 1PMID 42357947
- Numerous linked cases of acute genotype F hepatitis B virus infections in people living with HIV or on pre-exposure prophylaxisClin Microbiol Infect2026 Oct 16PMID 42887637
- Methodological considerations for indirect treatment comparisons of HIV incidence for long-acting injectable pre-exposure prophylaxisJ Comp Eff Res2026 Oct 15PMID 42878002Review
More infectious diseases trends
All specialties →Shorter antibiotic courses
Shorter durations of antibiotic therapy.
Key point: For children with acute uncomplicated UTIs, shorter-course antibiotic therapy appears comparable with longer-course therapy in efficacy and safety.
Candida auris
A multidrug-resistant fungus spreading in healthcare settings.
Metagenomic sequencing diagnostics
Metagenomic next-generation sequencing to identify pathogens.
RSV vaccines in older adults
RSV vaccination for adults aged 60 and older.
New antibiotics for resistant Gram-negatives
Cefiderocol, sulbactam-durlobactam and other new agents.
Shorter regimens for tuberculosis
Bedaquiline, pretomanid and other shorter TB regimens.
Key point: For adolescents aged 14 years and above and adults with MDR/RR-TB, 6-month BPaLM is recommended over 9-month or longer regimens.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
lenacapavir[tiab] OR cabotegravir[tiab] OR ("pre-exposure prophylaxis"[tiab] AND "long-acting"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.